Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: Leukotrienes, lipoxins and resolvins

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1063-1073

  Hersberger, Martin ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

atherosclerosis; inflammation; leukotrienes; lipoxins; lipoxygenase; resolvins

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; CD59 ANTIGEN; LEUKOTRIENE; LIPOXIN; OMEGA 3 FATTY ACID; RESOLVIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; LEUKOTRIENES; LIPOXINS; LIPOXYGENASE;

ANIMALIA;

EID: 77955454197     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.212     Document Type: Review

References (138)

1. Liscovitch M. Crosstalk among multiple signal-activated phospholipases. Trends Biochem Sci 1992;17:393-399
2. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24:1542-1548
3. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, et. al. Synergistic effect of cytochrome p450 epoxygenase cyp2j2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206.
4. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et. al. Genetic variation in soluble epoxide hydrolase (ephx2) and risk of coronary heart disease: The atherosclerosis risk in communities (aric) study. Hum Mol Genet 2006;15:1640-1649
5. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008;18:20-25
6. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008;118:161-180
7. Funk CD, FitzGerald GA. Cox-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50:470-479
8. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt B, et. al. Lipoxins and aspirin-triggered lipoxins in airway responses. Adv Exp Med Biol 2003;525:19-23.
9. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-361
10. Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med 2000;161(2 Pt 2):S2-6.
11. Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (mrp)-mediated transport of leukotriene c4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675-9682
12. Samuelsson B, Funk CD. Enzymes involved in the biosynthesis of leukotriene b4. J Biol Chem 1989;264:19469-19472
13. Maclouf JA, Murphy RC. Transcellular metabolism of neutrophil- derived leukotriene a4 by human platelets. A potential cellular source of leukotriene c4. J Biol Chem 1988;263 174-181
14. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006;58:375-388
15. Zarini S, Gijon MA, Ransome AE, Murphy RC, Sala A. Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci USA 2009;106:8296-301.
16. Fabre JE, Goulet JL, Riche E, Nguyen M, Coggins K, Offenbacher S, et. al. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest 2002;109:1373-1380
17. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357:1841-1854
18. Radmark O, Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. J Lipid Res 2009;50(Suppl):S40-5.
19. Mandal AK, Jones PB, Bair AM, Christmas P, Miller D, Yamin TT, et. al. The nuclear membrane organization of leukotriene synthesis. Proc Natl Acad Sci USA 2008;105: 20434-20439
20. Luo M, Jones SM, Peters-Golden M, Brock TG. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene b4 synthetic capacity. Proc Natl Acad Sci USA 2003;100: 12165-12170
21. Luo M, Jones SM, Flamand N, Aronoff DM, Peters-Golden M, Brock TG. Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem 2005; 280:40609-40616
22. Flamand N, Luo M, Peters-Golden M, Brock TG. Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J Biol Chem 2009;284:306-313
23. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and proresolution. Prostag Oth Lipid Mediat 2002;68-69:433-455
24. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994;269:27631-27634
25. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human alveolar macrophages have 15-lipoxygenase and generate 15(s)-hydroxy-5,8,11-cis- 13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993;92:1572-1579
26. Anderson GP, Coyle AJ. Th2 and 'th2-like' cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sci 1994;15:324-332
27. Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem Biophys Res Commun 1984; 118:943-949
28. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin e1 and protectin d1 activate inflammation-resolution programmes. Nature 2007;447:869-874
29. Rydberg EK, Krettek A, Ullstrom C, Ekstrom K, Svensson PA, Carlsson LM, et. al. Hypoxia increases ldl oxidation and expression of 15-lipoxygenase-2 in human macrophages. Arterioscler Thromb Vasc Biol 2004;24:2040-2045
30. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et. al. Interleukin-4-dependent production of ppar-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-382
31. Schild RL, Schaiff WT, Carlson MG, Cronbach EJ, Nelson DM, Sadovsky Y. The activity of ppar gamma in primary human trophoblasts is enhanced by oxidized lipids. J Clin Endocrinol Metab 2002;87:1105-1110
32. Ternowitz T, Andersen PH, Bjerring P, Fogh K, Schroder JM, Kragballe K. 15-Hydroxyeicosatetraenoic acid (15-hete) specifically inhibits the ltb4-induced skin response. Arch Dermatol Res 1989;281:401-405
33. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995;92:9475-9479
34. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin V, Serhan CN. Lipoxin a4 stable analogs are potent mimetics that stimulate human monocytes and thp-1 cells via a g-proteinlinked lipoxin a4 receptor. J Biol Chem 1997;272:6972-6978
35. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, et. al. Design of lipoxin a4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34:14609-14615
36. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005; 73:141-162
37. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, et. al. The lipoxin receptor alx: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58:463-487
38. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin a4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004;101:15178-15183
39. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin a4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol 2006;26:e14-7.
40. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et. al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037
41. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3:279-312.
42. Ariel A, Li PL, Wang W, Tang WX, Fredman G, Hong S, et. al. The docosatriene protectin d1 is produced by th2 skewing and promotes human t cell apoptosis via lipid raft clustering. J Biol Chem 2005;280:43079-43086
43. Butovich IA, Lukyanova SM, Bachmann C. Dihydroxydocosahexaenoic acids of the neuroprotectin d family: synthesis, structure, and inhibition of human 5-lipoxygenase. J Lipid Res 2006;47:2462-2474
44. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007;25:101-137
45. Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, Petasis NA, et. al. Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin d1. J Biol Chem 2009;284:17877-17882
46. Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. Resolvins e1 and d1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 2009;50:3613-3620
47. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-1204
48. Siddiqui RA, Harvey KA, Zaloga GP. Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J Nutr Biochem 2008;19:417-437
49. Wei C, Zhu P, Shah SJ, Blair IA. 15-Oxo-eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol Pharmacol 2009;76:516-525
50. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et. al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206:15-23.
51. Nigam S, Zafiriou MP, Deva R, Ciccoli R, Roux-Van der Merwe R. Structure, biochemistry and biology of hepoxilins: an update. Febs J 2007;274:3503-3512
52. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875
53. Varani J, Ward PA. Mechanisms of endothelial cell injury in acute inflammation. Shock 1994;2:311-319
54. Hafstrom I, Palmblad J, Malmsten CL, Radmark O, Samuelsson B. Leukotriene b4 - a stereospecific stimulator for release of lysosomal enzymes from neutrophils. Febs Lett 1981; 130:146-148
55. Rae SA, Smith MJ. The stimulation of lysosomal enzyme secretion from human polymorphonuclear leucocytes by leukotriene b4. J Pharm Pharmacol 1981;33:616-617
56. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005;4:664-672
57. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
58. Hua XY, Dahlen SE, Lundberg JM, Hammarstrom S, Hedqvist P. Leukotrienes c4, d4 and e4 cause widespread and extensive plasma extravasation in the guinea pig. Naunyn Schmiedebergs Arch Pharmacol 1985;330:136-141
59. Coles SJ, Neill KH, Reid LM, Austen KF, Nii Y, Corey EJ,et. al. Effects of leukotrienes c4 and d4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 1983;25:155-170
60. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes c4 and d4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-451
61. Echazarreta AL, Dahlen B, Garcia G, Agusti C, Barbera JA, Roca J, et. al. Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene d(4) in asthma. Am J Respir Crit Care Med 2001;164:202-206
62. Wang CG, Du T, Xu LJ, Martin JG. Role of leukotriene d4 in allergen-induced increases in airway smooth muscle in the rat. Am Rev Respir Dis 1993;148:413-417
63. Dahlen SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006;533:40-56.
64. Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL. Lipoxin a4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993;92:75-82.
65. Papayianni A, Serhan CN, Brady HR. Lipoxin a4 and b4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996;156:2264-2272
66. Scalia R, Gefen J, Petasis NA, Serhan CN, Lefer AM. Lipoxin a4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of p-selectin. Proc Natl Acad Sci USA 1997;94:9967-9972
67. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin- triggered-15r-lipoxin a(4) and lipoxin a(4). J Pharmacol Exp Ther 2002;300:385-392
68. Christie PE, Spur BW, Lee TH. The effects of lipoxin a4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992;145:1281-1284
69. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. Neutrophil- mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin a4 and novel lipoxin b4 stable analogues. J Clin Invest 1998;101:819-826
70. Serhan CN. Lipoxins and novel aspirin-triggered 15-epilipoxins (atl): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997;53:107-137
71. Fierro IM, Colgan SP, Bernasconi G, Petasis NA, Clish CB, Arita M, et. al. Lipoxin a4 and aspirin-triggered 15-epi-lipoxin a4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 2003;170:2688-2694
72. Ohira T, Bannenberg G, Arita M, Takahashi M, Ge Q, Van Dyke TE, et. al. A stable aspirin-triggered lipoxin a4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol 2004;173:2091-2098
73. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, et. al. Anti-inflammatory actions of lipoxin a4 and aspirintriggered lipoxin are socs-2 dependent. Nat Med 2006;12: 330-334
74. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (socs) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-529
75. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et. al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin e1. J Exp Med 2005;201:713-722
76. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17s-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278: 14677-14687
77. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, et. al. Novel docosanoids inhibit brain ischemiareperfusion- mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003;278:43807-43817
78. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, et. al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. Faseb J 2009;23:1946-1957
79. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin e1 regulates interleukin 23, interferon-gamma andlipoxin a4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9:873-879
80. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, et. al. Protectin d1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178:496-502.
81. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin e1 selectively interacts with leukotriene b4 receptor blt1 and chemr23 to regulate inflammation. J Immunol 2007;178:3912-3917
82. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin d1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004;101:8491-8496
83. Qin Q, Patil KA, Gronert K, Sharma SC. Neuroprotectin d1 inhibits retinal ganglion cell death following axotomy. Prostaglandins Leukot Essent Fatty Acids 2008;79:201-207
84. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005;280:15267-15278
85. Bazan NG. Neuroprotectin d1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 2009;50(Suppl):S400-5.
86. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, et. al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001;89:125-130
87. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, et. al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-126
88. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, et. al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10:966-973
89. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et. al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100:1238-1243
90. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong CH, et. al. Expression of 5-lipoxygenase and leukotriene a4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103:8161-8166
91. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, et. al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005;25:1665-1670
92. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, et. al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009;29:518-524
93. Seo KW, Lee SJ, Kim CE, Yun MR, Park HM, Yun JW, et. al. Participation of 5-lipoxygenase-derived ltb(4) in 4- hydroxynonenal-enhanced mmp-2 production in vascular smooth muscle cells. Atherosclerosis 2009;208:56-61
94. Back M, Hansson GK. Leukotriene receptors in therosclerosis. Ann Med 2006;38:493-502.
95. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene b4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002;22:443-449
96. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, et. al. Role of leukotriene b4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004;24:369-375
97. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et. al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350: 29-37.
98. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, et. al. Common polymorphisms of alox5 and alox5ap and risk of coronary artery disease. Hum Genet 2008;123:399-408.
99. Maznyczka A, Braund P, Mangino M, Samani NJ. Arachidonate 5-lipoxygenase (5-lo) promoter genotype and risk of myocardial infarction: a case-control study. Atherosclerosis 2008;199:328-332
100. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et. al. The gene encoding 5- lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-239
101. Helgadottir A, Gretarsdottir S, St. Clair D, Manolescu A, Cheung J, Thorleifsson G, et. al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76: 505-509
102. Linsel-Nitschke P, Gotz A, Medack A, Konig IR, Bruse P, Lieb W, et. al. Genetic variation in the arachidonate 5-lipoxygenase- activating protein (alox5ap) is associated with myocardial infarction in the German population. Clin Sci (Lond) 2008;115:309-315
103. Koch W, Hoppmann P, Mueller JC, Schomig A, Kastrati A. No association of polymorphisms in the gene encoding 5- lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet Med 2007;9: 123-129
104. van der Net JB, Versmissen J, Oosterveer DM, Defesche JC, Yazdanpanah M, Aouizerat BE, et. al. Arachidonate 5-lipoxygenase-activating protein (alox5ap) gene and coronary heart disease risk in familial hypercholesterolemia. Atherosclerosis 2008;203:472-478
105. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. wsee commentx werratum appears in JAMA. 2007 Sep 5;298(9):973x. J Am Med Assoc 2007;297:1551-1561
106. Girelli D, Martinelli N, Trabetti E, Olivieri O, Cavallari U, Malerba G, et. al. Alox5ap gene variants and risk of coronary artery disease: an angiography-based study. Eur J Hum Genet 2007;15:959-966
107. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 2006;37: 2007-2011
108. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, et. al. Effects of a 5-lipoxygenaseactivating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. J Am Med Assoc 2005;293:2245-2256
109. Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (alox5ap) gene and risk of stroke: a huge gene-disease association review and meta-analysis. Am J Epidemiol 2009;169:523-532
110. Maznyczka A, Mangino M, Whittaker A, Braund P, Palmer T, Tobin M, et. al. Leukotriene b4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenaseactivating protein gene associated with a risk of myocardial infarction. Clin Sci (Lond) 2007;112:411-416
111. Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R. The effect of montelukast on atherogenesis in apoe/ ldlr-double knockout mice. J Physiol Pharmacol 2008;59: 633-639
112. Ge S, Zhou G, Cheng S, Liu D, Xu J, Xu G, et. al. Antiatherogenic effects of montelukast associated with reduced mcp-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 2009;205:74-79
113. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et. al. Variant ltc(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55(Suppl 2): S28-31.
114. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009;64: 823-839
115. Freiberg JJ, Dahl M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG. Leukotriene c4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals. J Mol Cell Cardiol 2009;46:579-586
116. Freiberg JJ, Tybjaerg-Hansen A, Sillesen H, Jensen GB, Nordestgaard BG. Promotor polymorphisms in leukotriene c4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008;28:990-996
117. Iovannisci DM, Lammer EJ, Steiner L, Cheng S, Mahoney LT, Davis PH, et. al. Association between a leukotriene c4 synthase gene promoter polymorphism and coronary artery calcium in young women: The muscatine study. Arterioscler Thromb Vasc Biol 2007;27:394-399
118. Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostag Leukotr Ess 2007;77:67-77.
119. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002;2:787-795
120. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor alx. Prostaglandins Leukot Essent Fatty Acids 2005;73:163-177
121. Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15- lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002;68-69:263-290
122. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, Kuhn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur J Biochem 1993;213:251-261
123. Cathcart MK, McNally AK, Chisolm GM. Lipoxygenasemediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex. J Lipid Res 1991;32: 63-70.
124. Rankin SM, Parthasarathy S, Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of ldl by mouse peritoneal macrophages. J Lipid Res 1991;32:449-456
125. Sigari F, Lee C, Witztum JL, Reaven PD. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified ldl. Arterioscler Thromb Vasc Biol 1997;17: 3639-3645
126. Sakashita T, Takahashi Y, Kinoshita T, Yoshimoto T. Essential involvement of 12-lipoxygenase in regiospecific andstereospecific oxidation of low density lipoprotein by macrophages. Eur J Biochem 1999;265:825-831
127. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, et. al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996;98:2201-2208
128. Shen J, Kuhn H, Petho-Schramm A, Chan L. Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. Faseb J 1995;9:1623-1631
129. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. Faseb J 2008;22:3595-3606
130. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, et. al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo e-deficient mice. J Clin Invest 1999;103:1597-1604
131. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, et. al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein e-deficient mice. Circulation 2004;110:2024-2031
132. Harats D, Shaish A, George J, Mulkins M, Kurihara H, evkovitz H, et. al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in ldl receptordeficient mice. Arterioscler Thromb Vasc Biol 2000;20: 2100-2105
133. Poeckel D, Zemski Berry KA, Murphy RC, Funk CD. Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in apoe knockout mice. J Biol Chem 2009; 284:21077-21089
134. Neufeld EJ, Majerus PW, Krueger CM, Saffitz JE. Uptake and subcellular distribution of w3hxarachidonic acid in murine fibrosarcoma cells measured by electron microscope autoradiography. J Cell Biol 1985;101:573-581
135. Wittwer J, Marti-Jaun J, Hersberger M. Functional polymorphism in alox15 results in increased allele-specific transcription in macrophages through binding of the transcription factor spi1. Hum Mutat 2006;27:78-87.
136. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, et. al. A near null variant of 12/15-lox encoded by a novel snp in alox15 and the risk of coronary artery disease. Atherosclerosis 2008;198:136-144
137. Wittwer J, Bayer M, Mosandl A, Muntwyler J, Hersberger M. The c.-292c)t promoter polymorphism increases reticulocyte- type 15-lipoxygenase-1 activity and could be atheroprotective. Clin Chem Lab Med 2007;45:487-492
138. Hersberger M, Muller M, Marti-Jaun J, Heid IM, Coassin S, Young TF, et. al. No association of two functional polymorphisms in human alox15 with myocardial infarction. Atherosclerosis 2009;205:192-196